Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hu3S193 in Platinum-Resistant Ovarian Cancer
NCT00617773Phase 2Completed
- Sponsor
- Recepta Biopharma
- Start
- May 2008
- Primary completion
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hu3S193 in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Recepta Biopharma. Primary endpoint: Best Overall Response at 24 weeks. Started May 2008; status: completed.
02
Drugs
hu3S193
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00617773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617773.